IntelliPharmaCeutics International Inc.’s Big Gap Up Today Points to Less Stock Risks

 IntelliPharmaCeutics International Inc.'s Big Gap Up Today Points to Less Stock Risks

The stock of IntelliPharmaCeutics International Inc. (TSE:I) gapped up by $0.02 today and has $10.32 target or 158.00% above today’s $4.00 share price. The 7 months technical chart setup indicates low risk for the $124.77 million company. The gap was reported on Nov, 11 by Barchart.com. If the $10.32 price target is reached, the company will be worth $197.14M more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. About 21,830 shares traded hands. IntelliPharmaCeutics International Inc. (TSE:I) has risen 37.91% since April 7, 2016 and is uptrending. It has outperformed by 31.76% the S&P500.

Another recent and important IntelliPharmaCeutics International Inc. (TSE:I) news was published by Seekingalpha.com which published an article titled: “IntelliPharmaCeutics International Has Huge Upside With Limited Downside” on November 10, 2016.

IntelliPharmaCeutics International Inc is a Canada pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The company has a market cap of $124.77 million. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It currently has negative earnings. It has developed several drug delivery systems and a pipeline of products and product candidates in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain.

I.TO Company Profile

Intellipharmaceutics International Inc., incorporated on October 22, 2009, is a pharmaceutical firm specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, the Company has developed several drug delivery systems and a pipeline of products and product candidates at various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment